A breakthrough approach to cancer detection

Adela's platform can be applied across the cancer continuum

With a single, scalable platform, Adela is poised to address the unmet need broadly across multiple cancers and applications

Detect minimal residual disease (MRD) following surgery to guide use of adjuvant treatment and monitor for recurrence

Monitor for response in patients receiving immunotherapy

Early identification of multiple types of cancer for screening and detection